Table. State Rates of Naloxone Co-prescription Within 7 Days Among Medicare Part D Beneficiaries Receiving Prescription Opioids, 2016-2017a.
| State | Maximum MME/d | Opioids and Benzodiazepines | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any Opioid | <50 MME | 50-89 MME | ≥90 MME | Any Opioid and Benzodiazepine | Opioid and Benzodiazepine ≥300 d/y | Opioid and Benzodiazepine ≥300 d/y and ≥90 MME | ||||||||
| 2016 | 2017 | 2016 | 2017 | 2016 | 2017 | 2016 | 2017 | 2016 | 2017 | 2016 | 2017 | 2016 | 2017 | |
| Top 10 Statesb | ||||||||||||||
| Virginia | 1.2 | 33.0 | 0.1 | 9.3 | 0.5 | 28.5 | 6.3 | 141.1 | 2.5 | 76.3 | 7.8 | 225.5 | 12.1 | 298.9 |
| Vermont | 2.0 | 32.3 | NRc | 10.4 | NRc | 25.2 | 8.7 | 120.5 | 4.5 | 75.6 | 21.0 | 214.0 | 31.9 | 236.3 |
| Maryland | 4.2 | 16.9 | 0.2 | 1.9 | 1.3 | 9.4 | 20.1 | 78.4 | 8.6 | 33.4 | 32.8 | 118.2 | 43.0 | 148.1 |
| Tennessee | 3.7 | 13.5 | 0.2 | 2.5 | 1.9 | 8.6 | 14.9 | 51.5 | 5.7 | 21.5 | 10.9 | 43.8 | 17.8 | 68.5 |
| New Mexico | 7.7 | 11.8 | 1.5 | 1.7 | 5.3 | 8.3 | 34.6 | 58.8 | 13.8 | 23.4 | 46.7 | 66.2 | 65.4 | 97.9 |
| Oklahoma | 6.4 | 11.5 | 0.8 | 2.1 | 4.2 | 9.4 | 21.9 | 37.7 | 10.3 | 20.3 | 22.4 | 43.5 | 29.7 | 57.5 |
| North Carolina | 6.4 | 11.1 | 1.1 | 2.1 | 3.8 | 8.3 | 24.9 | 44.7 | 10.8 | 17.0 | 24.7 | 41.0 | 35.0 | 59.2 |
| Alaska | NRc | 9.8 | NAd | NRc | NRc | NRc | NRc | 37.2 | NRc | 20.8 | NAd | 42.3 | NAd | 47.4 |
| Arizona | 1.4 | 7.9 | 0.2 | 0.8 | 0.6 | 4.0 | 5.9 | 36.2 | 2.4 | 13.7 | 7.6 | 41.3 | 9.6 | 56.8 |
| West Virginia | 0.8 | 7.2 | NRc | 0.8 | NRc | 4.6 | 4.7 | 42.3 | 1.1 | 11.3 | 2.2 | 21.7 | 5.5 | 44.8 |
| Bottom 10 Statesb | ||||||||||||||
| South Dakota | 0.4 | 2.0 | NAd | NRc | NRc | NRc | NRc | 10.9 | NRc | 4.1 | NRc | NRc | NRc | NRc |
| Mississippi | 0.3 | 1.7 | NRc | 0.3 | NRc | 1.5 | 1.9 | 8.7 | 0.7 | 3.9 | 1.9 | 10.3 | 3.3 | 15.6 |
| Hawaii | NRc | 1.7 | NRc | NRc | NAd | NRc | NRc | 11.3 | NAd | 3.6 | NAd | NRc | NAd | NRc |
| North Dakota | 0.5 | 1.7 | NRc | NAd | NAd | NRc | NRc | 10.4 | NRc | 3.1 | NRc | NRc | NRc | NRc |
| New York | 0.6 | 1.5 | 0.1 | 0.2 | 0.3 | 1.1 | 3.5 | 8.7 | 1.4 | 3.5 | 5.3 | 12.0 | 7.7 | 16.8 |
| Illinois | 0.3 | 1.2 | NRc | 0.1 | 0.2 | 0.9 | 2.1 | 8.3 | 0.7 | 2.8 | 3.2 | 10.8 | 5.6 | 18.9 |
| Ohio | 0.7 | 1.2 | 0.2 | 0.2 | 0.5 | 1.0 | 3.3 | 6.1 | 1.2 | 2.8 | 3.1 | 8.2 | 4.8 | 13.0 |
| Louisiana | 0.9 | 1.0 | 0.1 | 0.1 | 0.5 | 0.5 | 4.7 | 5.3 | 1.9 | 1.9 | 6.0 | 5.9 | 10.3 | 10.0 |
| Iowa | 0.5 | 0.8 | NRc | NRc | NRc | 0.4 | 2.6 | 4.9 | 0.8 | 1.4 | 4.4 | 5.6 | 7.8 | 9.8 |
| Nebraska | 0.4 | 0.7 | NRc | NRc | NRc | NRc | 2.4 | 4.4 | 0.9 | 1.7 | NRc | 6.6 | NRc | NRc |
Abbreviations: MME, morphine milligram equivalents; NA, not available; NR, not reported.
Rates are per 1000 Medicare Part D beneficiaries receiving opioids in each category. Comparison of overall co-prescribing rates for “any opioid” in other states between 2016 and 2017: Washington, 3.1-6.9; Utah, 5.5-6.8; Colorado, 2.2-6.5; Wisconsin, 1.9-6.3; Wyoming, 1.7-5.6; Delaware, 1.4-5.2; Massachusetts, 4.0-5.0; Oregon, 2.1-4.8; District of Columbia, 1.1-4.7; Connecticut, 3.0-4.0; Missouri, 0.6-4.0; Nevada, 1.4-3.7; Pennsylvania, 1.0-3.2; Kentucky, 1.4-3.2; Michigan, 0.9-3.1; South Carolina, 1.1-2.9; Rhode Island, 2.4-2.9; Florida, 0.7-2.8; New Hampshire, 1.9-2.5; Kansas, 0.8-2.5; Alabama, 0.9-2.5; Montana, 0.8-2.5; New Jersey, 0.4-2.4; Maine, 1.0-2.4; California, 1.4-2.4; Minnesota, 0.8-2.3; Texas, 0.9-2.2; Idaho, 0.6-2.2; Arkansas, 0.3-2.1; Indiana, 0.6-2.1; Georgia, 0.8-2.1.
States are ordered based on descending rates of overall co-prescribing.
Data have been suppressed based on privacy requirements.
No data for the measure.